Company News

 

Tauriga Sciences Inc. to Form Wholly Owned Subsidiary Focused on the Development …  View


Tauriga Sciences, Inc. announced that it has secured additional capital..  View


2014 – 2015 Financials Reported – Company On Track To Regain Reporting Status. View

LATEST TAURIGA SCIENCES UPDATES

TAURIGA SCIENCES, INC. CONFIRMS THE TIMELY SUBMISSION OF ITS EXPERT REPORT TO FEDERAL DISTRICT COURT NEW JERSEY; REPORT OPINES THAT TAURIGA SUFFERED LOSSES OF $3,995,000 USD AT MINIMUM

NEW YORK, NY — (Marketwired) — 09/07/17 — Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today confirmed the timely submission of its Expert Report to Federal District Court New Jersey …

Read More

TAURIGA SCIENCES, INC. TAKING IMMEDIATE AND CONCRETE STEPS TO EXTINGUISH THE CANADIAN CEASE TRADE ORDER INSTITUTED BY AUTORITE DES MARCHES FINANCIERS (QUEBEC BASED REGULATORY AUTHORITY)

NEW YORK, NY — (Marketwired) — 09/06/17 — Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced that it is taking immediate and concrete steps to extinguish the Canadian Cease Trade…

Read More

TAURIGA SCIENCES INC. FULLY RETIRES $60,950 USD FACE VALUE 12.00% CONVERTIBLE DEBENTURE ISSUED TO ADAR BAYS LLC ON DECEMBER 19, 2016

NEW YORK, NY, Aug 09, 2017 (Marketwired via COMTEX) — NEW YORK, NY–(Marketwired – Aug 9, 2017) – Tauriga Sciences, Inc. (otc pink:TAUG) (“Tauriga” or the “Company”), engaged in building of businesses in the life sciences space…

Read More

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.

Balanced Innovation and Commercialization

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and on developing a proprietary synthetic biology platform technology through its wholly-owned Pilus Energy subsidiary.

The Company’s business model is to create an attractive and balanced portfolio of life sciences assets without typical clinical regulatory timelines.

Tauriga’s main focus for the last year has been getting audited financials and relisted on BB. Due to what we believe was gross malpractice by our auditors, TAUG was delisted from the BB. But we are always looking for exciting opportunities to increase shareholder value.
Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor.
Recently the Company added Frank Orlowski, Sr. Director at Pfizer (PFE); and Keith Berman  CEO of Digital Diagnostics Inc (DECN). The Company remains committed to finding the right opportunity to joint venture or merge with.